"This patent application covers an important element of our proprietary Cymerus stem cell manufacturing technology," said Ross Macdonald, Ph.D., Cynata's Chief Executive Officer. "This patent and others we have filed continue to strengthen our comprehensive patent portfolio relating to the scalable manufacture of consistent, high-quality mesenchymal stem cell therapeutic products targeting a range of devastating diseases worldwide."
The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.
Cynata anticipates that the patent will be granted by October 2017, with an expiration date of 1 February 2028.
EndsCONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Andrew Ramadge, Australia Media Contact, 0475 797 471, andrew.ramadge@mcpartners.com.au
About Cynata Therapeutics (ASX: CYP)Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
Cynata Therapeutics Limited
Suite 1, 1233 High Street, Armadale, Victoria 3143, Australia PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com
ABN - 98 104 037 372
Cynata Therapeutics Ltd. published this content on 19 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 June 2017 05:05:34 UTC.
Original documenthttp://cynata.com/wp-content/uploads/2017/06/17.06.19.United-States-Patent-for-Core-Cynata-Technology.pdf
Public permalinkhttp://www.publicnow.com/view/683DC03F988FC477F6936DB0AE575EA86A4F3D0D